Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Inv. presentation
Quarterly results
Appointed director
CC transcript
Auditor change
Director departure
JUNIPER PHARMACEUTICALS INC (JNP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2018 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Certificate of Incorporation of Juniper Pharmaceuticals, Inc",
"Amended and Restated Bylaws of Juniper Pharmaceuticals, Inc"
08/09/2018 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Juniper Pharmaceuticals Reports Second Quarter 2018 Financial and Operating Results Signs Agreement to be Acquired by Catalent, Inc. CRINONE ® Revenues Increased 12% and Juniper Pharma Services Revenues Increased 41% for the Six-months Ended June 30, 2018 vs. Prior Year"
07/03/2018 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...
Docs: "Agreement and Plan of Merger, by and among Catalent Pharma Solutions, Inc., Catalent Boston, Inc., and Juniper Pharmaceuticals, Inc",
"Amendment to the Amended and Restated By-laws of Juniper Pharmaceuticals, Inc",
"Juniper Pharmaceuticals Signs Definitive Agreement to be"
05/10/2018 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Juniper Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results Core Businesses Driving Strong Financial Performance CRINONE ® Revenues Increased 30% and Juniper Pharma Services Revenues Increased 55% Year-over-Year Conference Call at 8:30 a.m. EST Today"
04/25/2018 8-K Quarterly results
03/21/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K"
03/08/2018 8-K Results of Operations and Financial Condition, Shareholder Nominations Pursuant to Exchange Act Rule 14a-11, Financial Statem...
Docs: "FORM 8-K",
"Juniper Pharmaceuticals Reports Full-Year 2017 Financial and Operating Results Full Year CRINONE ® Revenues Increased 20% and Juniper Pharma Services Revenues Increased 32% Year-over-Year Ended 2017 Cash Flow Positive; Company Expects Trend to Continue in 2018 Conference Call at 8:30 a.m. EST Today"
02/05/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : January 31, 2018 JUNIPER PHARMACEUTICALS, INC. Delaware 001-10352 59-2758596 33 Arch Street Suite 3110 Boston, Massachusetts 02110 Registrant's telephone number, including area code: 639-1500",
"Juniper Pharmaceuticals to Explore Strategic Alternatives"
01/08/2018 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : January 7, 2018 JUNIPER PHARMACEUTICALS, INC. Delaware 001-10352 59-2758596 33 Arch Street Suite 3110 Boston, Massachusetts 02110 Registrant's telephone number, including area code: 639-1500",
"Juniper Pharmaceuticals Announces 4.5-Year Extension through 2024 of CRINONE ® Supply Agreement with Merck KGaA, Darmstadt, Germany"
11/07/2017 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : November 2, 2017 JUNIPER PHARMACEUTICALS, INC. Delaware 001-10352 59-2758596 33 Arch Street Suite 3110 Boston, Massachusetts 02110 Registrant's telephone number, including area code: 639-1500",
"Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating Results CRINONE ® Revenues Increased 19% and Juniper Pharma Services Revenues Increased 38% Year-over-Year Implemented Strategic Reprioritization",
"Script of the Juniper Pharmaceuticals Q3 2017 Financial Results Call"
11/02/2017 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : November 2, 2017 JUNIPER PHARMACEUTICALS, INC. Delaware 001-10352 59-2758596 33 Arch Street Suite 3110 Boston, Massachusetts 02110 Registrant's telephone number, including area code: 639-1500",
"Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating Results CRINONE ® Revenues Increased 19% and Juniper Pharma Services Revenues Increased 38% Year-over-Year Implemented Strategic Reprioritization"
09/19/2017 8-K Quarterly results
09/11/2017 8-K Quarterly results
08/03/2017 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Juniper Pharmaceuticals Reports Second Quarter 2017 Financial and Operating Results CRINONE ® Revenues Increased 30% and Juniper Pharma Services Revenues increase 30% Year-over-Year"
07/05/2017 8-K Form 8-K - Current report
05/04/2017 8-K Form 8-K - Current report
03/07/2017 8-K Form 8-K - Current report
12/23/2016 8-K Form 8-K - Current report
11/16/2016 8-K Form 8-K - Current report
11/15/2016 8-K Form 8-K - Current report
10/24/2016 8-K Form 8-K - Current report
08/04/2016 8-K Form 8-K - Current report
07/28/2016 8-K Form 8-K - Current report
07/20/2016 8-K Form 8-K - Current report
06/15/2016 8-K Form 8-K - Current report
06/02/2016 8-K Form 8-K - Current report
05/04/2016 8-K Form 8-K - Current report
03/24/2016 8-K Form 8-K - Current report
03/10/2016 8-K Form 8-K - Current report
11/10/2015 8-K Quarterly results
Docs: "Juniper Pharmaceuticals Reports Third Quarter 2015 Financial Results"
10/20/2015 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
07/22/2015 8-K Appointed a new director
Docs: "Juniper Pharmaceuticals Announces Board Changes",
"Juniper Pharmaceuticals Announces Board Changes"
07/10/2015 8-K Resignation/termination of a director
05/28/2015 8-K Appointed a new director
Docs: "Juniper Pharmaceuticals Appoints James A. Geraghty to Board of Directors"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy